AbbVie Inc. (ABBV)

Pharmaceutical Preparations

Latest Price

$250.94

TTM P/E

123.62

Normalized P/E

64.33

Div Yield

2.69%

Book Value

0.80

P/B Ratio

312.43

Valuation metrics

Norm. op. income: $13.0B (median of 7yr)

Tax rate: 12%

Discount rate: 10%

Growth assumption: zero (EPV is a no-growth value)

Earnings Power Value

$29.53

88% downside

Base FCF: $22.0B (median of recent 5yr)

Growth: 5%/yr (median YOY, capped at 25%)

Discount rate: 10%

Terminal growth: 3%

Projection horizon: 10 years

DCF Fair Value

$178.07

29% downside

EPS: $2.36

Target P/E: 64×

Formula: EPS × P/E

P/E Fair Value

$151.04

40% downside

68.8% held by institutions

Institution	Shares	Value	Ownership %	Change	Filing Date
BlackRock, Inc.	150.75M	$32.79B	8.52%	-424.9K	2026-03-31
VANGUARD CAPITAL MANAGEMENT LLC	114.88M	$24.98B	6.49%	--	2026-03-31
STATE STREET CORP	81.22M	$17.66B	4.59%	+276.6K	2026-03-31
VANGUARD PORTFOLIO MANAGEMENT LLC	49.52M	$10.77B	2.80%	--	2026-03-31
GEODE CAPITAL MANAGEMENT, LLC	46.74M	$10.14B	2.64%	+2.11M	2026-03-31
MORGAN STANLEY	38.02M	$8.27B	2.15%	-2.03M	2026-03-31
Capital Research Global Investors	31.25M	$6.80B	1.77%	+5.85M	2026-03-31
BANK OF AMERICA CORP /DE/	23.94M	$5.21B	1.35%	-1.89M	2026-03-31
FMR LLC	21.76M	$4.73B	1.23%	-846.7K	2026-03-31
NORTHERN TRUST CORP	21.21M	$4.61B	1.20%	-522.5K	2026-03-31